The Moderna cancer vaccine offers hope — now we must speed up personalized therapies

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Focus: Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough  Reuters

A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences – already